TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00822419
Drug: non-drug cream
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be put on the skin
Study: NCT00868140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily
Study: NCT02395549
Drug: 0.375% (w/w) MTC896 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% (w/w) MTC896 Gel
Study: NCT02395549
Drug: 0.75% (w/w) MTC896 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% (w/w) MTC896 Gel
Study: NCT02395549
Drug: 1.5% (w/w) MTC896 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% (w/w) MTC896 Gel
Study: NCT00457821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given q12h for 28 days each in Part 1 and Part 2 of the study
Study: NCT00161577
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketorolac every 6 hours for 24 hours
Study: NCT03057041
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
Study: NCT03057041
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
Study: NCT01222091
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
Study: NCT00978055
Drug: 1: Liothyronine Sodium Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting
Study: NCT00978055
Drug: 2: Cytomel® Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting
Study: NCT01888536
Drug: Placebo(for Pregabalin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mimic Pregabalin 75mg capsule
Study: NCT01888536
Drug: Placebo(for Limaprost)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mimic Limaprost tablet
Study: NCT02039219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
Study: NCT02039219
Drug: 10 mg Obeticholic Acid (OCA)
Normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
Study: NCT03576066
Drug: ABI-H0731
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
Study: NCT03576066
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching ABI-0731 tablets orally QD.
Study: NCT02340247
Drug: Chenodeoxycholic Acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00673205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00695955
Drug: Azilsartan medoxomil with or without add-on chlorthalidone
Normalized name: azilsartan medoxomil / chlorthalidone Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
Study: NCT00695955
Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
Study: NCT01562314
Drug: GWP42003
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 5 50 mg capsules taken BID
Study: NCT01562314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 5 matching capsules taken BID
Study: NCT05305222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT01190761
Drug: Reminyl 4 mg Tablet, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
Study: NCT02172131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01190475
Drug: Active treatment with a high dose of BGS649
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01190475
Drug: Active treatment with a low dose of BGS649
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01190475
Drug: Placebo treatment to blind study
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03505788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
Study: NCT03834610
Drug: L-arginine 5 gm oral caps
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral L-arginine 5 gm daily for 8 weeks
Study: NCT03389724
Drug: Capoten®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
Study: NCT01775579
Drug: Glucophage SR tablet 750 mg, Crestor tablet 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01516580
Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses.
Study: NCT02030925
Drug: IW-3718
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02030925
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02312999
Drug: Plasmalyte
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00613002
Drug: testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily transdermal testosterone gel, 300 mcg
Study: NCT00613002
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily transdermal placebo gel
Study: NCT01281254
Drug: AMG386 plus PLD
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
Study: NCT01281254
Drug: Placebo plus PLD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
Study: NCT00113399
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01106651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
Study: NCT00318747
Drug: Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02576041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once a day during 7+3 days run in period
Study: NCT01535599
Drug: AL-60371, 0.3% Otic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02724917
Drug: APN1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solid dose form of APN1125
Study: NCT02724917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT01672463
Drug: OKN-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.
Study: NCT01984463
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
Study: NCT02959541
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03172325
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg Methotrexate is weekly administered to all the patients.
Study: NCT03172325
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At least 1 mg Folic acid is daily administered to all the patients.
Study: NCT03172325
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg Prednisolone is daily administered to all the patients.
Study: NCT02130830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
Study: NCT02668770
Drug: MGN1703
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.
Study: NCT02120300
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally
Study: NCT02120300
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet administered orally once daily
Study: NCT03466099
Drug: KVD001 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal KVD001 Injection
Study: NCT03208907
Drug: DHA-PQP coadministered with PQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
Study: NCT01114971
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)
Study: NCT00791479
Drug: Placebo solution and Lifestyle Measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection once-weekly for up to 12 weeks
Study: NCT00381511
Drug: low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00115479
Drug: intensive insulin therapy to maintain normoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03119181
Drug: Tymbion Lidocaine/epinephrine solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The external ear canal will be filled with Tymbion drug solution
Study: NCT00348699
Drug: AFP464
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02152371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT02916641
Drug: Fuzhenghuayu
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01367418
Drug: Patient controlled analgesia (PCA)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/ml
Study: NCT02052336
Drug: CJ-12420 200mg + Clarithromycin 500mg
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Study: NCT02052336
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
Study: NCT01408550
Drug: NPB-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin
Study: NCT01408550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline
Study: NCT03571802
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~* There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery.
Study: NCT00099944
Drug: LAF237 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00634712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01441908
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg or 80mg dose 28 days for 6 month period
Study: NCT00050531
Drug: Peg-alpha interferon (Peg-Intron)
Normalized name: PEG-3 alpha-linolenamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-IFN 0.5 mcg/kg each week subcutaneously.
Study: NCT02099877
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural analgesia will be initiated with 100µg of epidural fentanyl
Study: NCT03985410
Drug: ETX2514
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT03985410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00027378
Drug: fluoxetine (Prozac)
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
Study: NCT00027378
Drug: Placebo plus Treatment As Usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
Study: NCT02321189
Drug: LONGEVINEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
Study: NCT02321189
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: let everyone of the participants oral 1 capsule containing 100 mg placebo
Study: NCT00771706
Drug: Proton Pump Inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
Study: NCT00771706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
Study: NCT01895231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01097629
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study: NCT01456195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam placebo-matching tablets
Study: NCT01373684
Drug: Nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
Study: NCT01851486
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03167112
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
Study: NCT03167112
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
Study: NCT00956943
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch
Study: NCT01208129
Drug: NAB001
Approvals — FDA: no, EMA: no, PMDA: no
Description: nail lacquer, once daily, 52 weeks
Study: NCT01208129
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: nail lacquer, once daily, 52 weeks
Study: NCT00247104
Drug: Cranberries - Vaccinium macrocarpon
Normalized name: Vaccinium macrocarpon whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01667874
Drug: Collatamp G sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collatamp G is an antibiotic impregnated sponge
Study: NCT02566733
Drug: Remiva
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion of remifentanil (generic drug, Remiva™)
Study: NCT02144272
Drug: LY3114062 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3114062 administered SC.
Study: NCT02144272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered SC.
Study: NCT02144272
Drug: LY3114062 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3114062 administered IV.
Study: NCT02187276
Drug: cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
Study: NCT00611442
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gelcap, taken at noon the day prior to the colonoscopy
Study: NCT01587261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
Study: NCT05055232
Drug: XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
Study: NCT01035437
Drug: HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH in D5W, 4.0 mg/m2 infused over 1 hour
Study: NCT00420004
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mg and 6-mg tablets
Study: NCT00420004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04629287
Drug: KPCXM18
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
Study: NCT01713361
Drug: ISIS-FXIRx Dose #2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
Study: NCT01713361
Drug: ISIS-FXIRx Dose #3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
Study: NCT01304069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be given orally placebo twice a day for 7 days prior to the study.
Study: NCT01304069
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
Study: NCT04629287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
Study: NCT02379221
Drug: Injectable
Normalized name: Injectable Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
Study: NCT00584090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent of 5-10 mg po qd for 1 month
Study: NCT03341078
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be orally ingested twice daily for 6 weeks.
Study: NCT01576419
Drug: PG201 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
Study: NCT00303771
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00303771
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006042
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes